{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:11:16Z","timestamp":1790928676461,"version":"4.1.0"},"reference-count":96,"publisher":"American Academy of Pediatrics (AAP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:p>Therapeutic drug monitoring (TDM) is indicated for drugs with narrow therapeutic indices, whereby clinicians can adjust drug dosing to promote efficacy while limiting toxicity risk. Such monitoring is particularly important in managing infectious diseases, as both patient- and organism-specific factors must be considered to achieve optimal clinical responses. Innovation in pediatric TDM lags behind adults, largely due to a paucity of data and feasibility issues with lab draws and pharmacy resources. Emerging techniques in pharmacokinetic (PK) modeling, PK study design, flexible sampling strategies, and reduced sample volume requirements are particularly promising for TDM advancement in neonates and children. In this article, we discuss recent advancements in vancomycin TDM as a model case. Vancomycin is commonly used to treat serious gram-positive infections in children, and monitoring was historically performed using trough concentration\u2013based guidance. Emerging data suggest that vancomycin troughs are not reliable surrogates for efficacy or toxicity and that trough-based monitoring is associated with increased risk of nephrotoxicity without clinical benefits. The area under the concentration-time curve (AUC) is the optimal pharmacokinetic-pharmacodynamic metric to measure overall vancomycin exposures, and consensus infectious diseases and pharmacist society guidance has formally recommended a shift toward AUC-based monitoring and away from trough-based monitoring in all age groups\u2014including in neonates and children. We compare approaches to TDM in infectious diseases and summarize the body of literature describing application of vancomycin AUC-guided monitoring in children and neonates. Finally, we highlight opportunities and potential barriers to implementation of AUC-guided TDM in pediatric populations.<\/jats:p>","DOI":"10.1542\/peds.2025-073013","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:02:16Z","timestamp":1766016136000},"source":"Crossref","is-referenced-by-count":6,"title":["Advances in Pediatric Therapeutic Drug Monitoring"],"prefix":"10.1542","volume":"157","author":[{"given":"Sarah A.","family":"Coggins","sequence":"first","affiliation":[{"name":"1Division of Neonatology, Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania"},{"name":"2Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly C.","family":"Wade","sequence":"additional","affiliation":[{"name":"1Division of Neonatology, Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania"},{"name":"2Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Downes","sequence":"additional","affiliation":[{"name":"2Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania"},{"name":"3Division of Infectious Diseases, Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"2025123118585395600_r1","first-page":"1","volume-title":"Therapeutic Drug Monitoring Data","author":"Dasgupta","year":"2020","edition":"4th ed"},{"issue":"3","key":"2025123118585395600_r2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/FTD.0b013e3181dd51ef","article-title":"Therapeutic drug monitoring in pediatrics: how do children differ?","volume":"32","author":"Macleod","year":"2010","journal-title":"Ther Drug Monit."},{"issue":"8","key":"2025123118585395600_r3","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/j.clinthera.2019.05.008","article-title":"Hospital-wide description of clinical indications for pediatric anti-infective use","volume":"41","author":"Williams","year":"2019","journal-title":"Clin Ther."},{"issue":"9","key":"2025123118585395600_r4","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1055\/s-0033-1361933","article-title":"Medication use in the neonatal intensive care unit","volume":"31","author":"Hsieh","year":"2014","journal-title":"Am J Perinatol."},{"key":"2025123118585395600_r5","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jpeds.2021.08.075","article-title":"Medication use in the neonatal intensive care unit and changes from 2010 to 2018","volume":"240","author":"Stark","year":"2022","journal-title":"J Pediatr."},{"issue":"suppl 1","key":"2025123118585395600_r6","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1086\/491712","article-title":"The pharmacokinetic and pharmacodynamic properties of vancomycin","volume":"42","author":"Rybak","year":"2006","journal-title":"Clin Infect Dis."},{"issue":"1","key":"2025123118585395600_r7","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1128\/AAC.31.1.52","article-title":"Vancomycin pharmacokinetics and dose recommendations for preterm infants","volume":"31","author":"James","year":"1987","journal-title":"Antimicrob Agents Chemother."},{"issue":"5","key":"2025123118585395600_r8","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1128\/AAC.01718-13","article-title":"Determination of vancomycin pharmacokinetics in neonates to develop practical initial dosing recommendations","volume":"58","author":"Kim","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"issue":"1","key":"2025123118585395600_r9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2125.2006.02725.x","article-title":"Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance","volume":"63","author":"Anderson","year":"2007","journal-title":"Br J Clin Pharmacol."},{"issue":"4","key":"2025123118585395600_r10","doi-asserted-by":"crossref","first-page":"e0189921","DOI":"10.1128\/aac.01899-21","article-title":"Optimizing vancomycin dosing and monitoring in neonates and infants using population pharmacokinetic modeling","volume":"66","author":"Jarugula","year":"2022","journal-title":"Antimicrob Agents Chemother."},{"issue":"11","key":"2025123118585395600_r11","doi-asserted-by":"crossref","first-page":"6454","DOI":"10.1128\/AAC.03620-14","article-title":"Association between vancomycin trough concentration and area under the concentration-time curve in neonates","volume":"58","author":"Frymoyer","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"issue":"1","key":"2025123118585395600_r12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s13318-021-00730-z","article-title":"Pharmacokinetics of vancomycin in critically ill children: a systematic review","volume":"47","author":"Akunne","year":"2022","journal-title":"Eur J Drug Metab Pharmacokinet."},{"issue":"2","key":"2025123118585395600_r13","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1542\/peds.2014-3819","article-title":"Neonatal acute kidney injury","volume":"136","author":"Selewski","year":"2015","journal-title":"Pediatrics."},{"issue":"10","key":"2025123118585395600_r14","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1007\/s00467-010-1533-y","article-title":"Reference values for serum creatinine in children younger than 1\u00a0year of age","volume":"25","author":"Boer","year":"2010","journal-title":"Pediatr Nephrol."},{"issue":"1","key":"2025123118585395600_r15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkz325","article-title":"Mechanisms of antimicrobial-induced nephrotoxicity in children","volume":"75","author":"Downes","year":"2020","journal-title":"J Antimicrob Chemother."},{"issue":"10","key":"2025123118585395600_r16","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1136\/archdischild-2021-323429","article-title":"Vancomycin-associated acute kidney injury epidemiology in children: a systematic review","volume":"107","author":"Williams","year":"2022","journal-title":"Arch Dis Child."},{"issue":"11","key":"2025123118585395600_r17","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1093\/cid\/ciz051","article-title":"Vancomycin area under the curve and acute kidney injury: a meta-analysis","volume":"69","author":"Aljefri","year":"2019","journal-title":"Clin Infect Dis."},{"issue":"11","key":"2025123118585395600_r18","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm."},{"issue":"1","key":"2025123118585395600_r19","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1128\/AAC.01653-13","article-title":"Are vancomycin trough concentrations adequate for optimal dosing?","volume":"58","author":"Neely","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"issue":"12","key":"2025123118585395600_r20","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1177\/10600280231160571","article-title":"Correlation of calculated vancomycin trough concentrations and exposure: a Monte Carlo simulation","volume":"57","author":"Haag","year":"2023","journal-title":"Ann Pharmacother."},{"issue":"2","key":"2025123118585395600_r21","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s40272-018-0282-4","article-title":"The relationship between vancomycin trough concentrations and AUC\/MIC ratios in pediatric patients: a qualitative systematic review","volume":"20","author":"Tkachuk","year":"2018","journal-title":"Paediatr Drugs."},{"issue":"4","key":"2025123118585395600_r22","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/FTD.0000000000001075","article-title":"Area-under-curve-guided versus trough-guided monitoring of vancomycin and its impact on nephrotoxicity: a systematic review and meta-analysis","volume":"45","author":"Lim","year":"2023","journal-title":"Ther Drug Monit."},{"issue":"12","key":"2025123118585395600_r23","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1093\/jac\/dkad333","article-title":"Comparison of the incidence of vancomycin-associated nephrotoxicity following the change from trough-guided dosing to AUC-guided doing using trough-only data","volume":"78","author":"Yamada","year":"2023","journal-title":"J Antimicrob Chemother."},{"issue":"1","key":"2025123118585395600_r24","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"66","author":"Rybak","year":"2009","journal-title":"Am J Health Syst Pharm."},{"issue":"3","key":"2025123118585395600_r25","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/cid\/cir034","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis."},{"issue":"2","key":"2025123118585395600_r26","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/00003088-200948020-00001","article-title":"Therapeutic drug monitoring of aminoglycosides in neonates","volume":"48","author":"Touw","year":"2009","journal-title":"Clin Pharmacokinet."},{"key":"2025123118585395600_r27","first-page":"914","volume-title":"Red Book: 2021\u20132024 Report of the Committee on Infectious Diseases","author":"AAP Committee on Infectious Diseases","year":"2021","edition":"32nd ed"},{"issue":"3","key":"2025123118585395600_r28","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1309\/AJCPDSYS0DVLKFOH","article-title":"What proportion of vancomycin trough levels are drawn too early?: frequency and impact on clinical actions","volume":"137","author":"Morrison","year":"2012","journal-title":"Am J Clin Pathol."},{"issue":"12","key":"2025123118585395600_r29","first-page":"30","article-title":"Implications of vancomycin troughs drawn earlier than current guidelines","volume":"32","author":"Sklansky","year":"2015","journal-title":"Fed Pract."},{"issue":"6","key":"2025123118585395600_r30","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1309\/AJCPKQ6EAH7OYQLB","article-title":"An intervention to improve the timing of vancomycin levels","volume":"140","author":"Melanson","year":"2013","journal-title":"Am J Clin Pathol."},{"issue":"1","key":"2025123118585395600_r31","first-page":"41","article-title":"Vancomycin AUC\/MIC and corresponding troughs in a pediatric population","volume":"22","author":"Kishk","year":"2017","journal-title":"J Pediatr Pharmacol Ther."},{"issue":"10","key":"2025123118585395600_r32","doi-asserted-by":"crossref","first-page":"e244","DOI":"10.1097\/INF.0000000000000817","article-title":"Correlation of a vancomycin pharmacokinetic model and trough serum concentrations in pediatric patients","volume":"34","author":"Ploessl","year":"2015","journal-title":"Pediatr Infect Dis J."},{"issue":"1","key":"2025123118585395600_r33","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/bcpt.13303","article-title":"Desired vancomycin trough concentration to achieve an AUC0\u201324 \/MIC \u2265400 in Chinese children with complicated infectious diseases","volume":"126","author":"Zhang","year":"2020","journal-title":"Basic Clin Pharmacol Toxicol."},{"issue":"6","key":"2025123118585395600_r34","doi-asserted-by":"crossref","first-page":"e00885","DOI":"10.1002\/prp2.885","article-title":"The relationship between vancomycin AUC\/MIC and trough concentration, age, dose, renal function in Chinese critically ill pediatric patients","volume":"9","author":"Chen","year":"2021","journal-title":"Pharmacol Res Perspect."},{"issue":"8","key":"2025123118585395600_r35","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/cid\/cir078","article-title":"Vancomycin: we can\u2019t get there from here","volume":"52","author":"Patel","year":"2011","journal-title":"Clin Infect Dis."},{"key":"2025123118585395600_r36","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.addr.2014.05.016","article-title":"Innovative approaches to optimizing the delivery of vancomycin in individual patients","volume":"77","author":"Pai","year":"2014","journal-title":"Adv Drug Deliv Rev."},{"issue":"3","key":"2025123118585395600_r37","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/0897190016642692","article-title":"Are vancomycin trough concentrations of 15 to 20\u00a0mg\/L associated with increased attainment of an AUC\/MIC\u2009\u2265\u2009400 in patients with presumed MRSA infection?","volume":"30","author":"Hale","year":"2017","journal-title":"J Pharm Pract."},{"issue":"5","key":"2025123118585395600_r38","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/cid\/ciu398","article-title":"Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?","volume":"59","author":"Lodise","year":"2014","journal-title":"Clin Infect Dis."},{"issue":"4","key":"2025123118585395600_r39","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1097\/INF.0b013e318286378e","article-title":"Improved vancomycin dosing in children using area under the curve exposure","volume":"32","author":"Le","year":"2013","journal-title":"Pediatr Infect Dis J."},{"issue":"9","key":"2025123118585395600_r40","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1097\/INF.0000000000001943","article-title":"Optimizing vancomycin monitoring in pediatric patients","volume":"37","author":"Alsultan","year":"2018","journal-title":"Pediatr Infect Dis J."},{"issue":"4","key":"2025123118585395600_r41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.01647-17","article-title":"Evaluating the relationship between vancomycin trough concentration and 24-hour area under the concentration-time curve in neonates","volume":"62","author":"Tseng","year":"2018","journal-title":"Antimicrob Agents Chemother."},{"issue":"4","key":"2025123118585395600_r42","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1086\/600884","article-title":"Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients","volume":"49","author":"Lodise","year":"2009","journal-title":"Clin Infect Dis."},{"issue":"2","key":"2025123118585395600_r43","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1128\/AAC.01568-12","article-title":"Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter","volume":"57","author":"van Hal","year":"2013","journal-title":"Antimicrob Agents Chemother."},{"issue":"12","key":"2025123118585395600_r44","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.2215\/CJN.05920616","article-title":"Vancomycin and the risk of AKI: A systematic review and meta-analysis","volume":"11","author":"Sinha Ray","year":"2016","journal-title":"Clin J Am Soc Nephrol."},{"issue":"6","key":"2025123118585395600_r45","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/cid\/ciaa303","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"71","author":"Rybak","year":"2020","journal-title":"Clin Infect Dis."},{"issue":"6","key":"2025123118585395600_r46","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1177\/08971900211012395","article-title":"Assessment of the implementation of AUC dosing and monitoring practices with vancomycin at hospitals across the United States","volume":"35","author":"Bradley","year":"2022","journal-title":"J Pharm Pract."},{"issue":"5","key":"2025123118585395600_r47","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1128\/AAC.03147-14","article-title":"Optimizing the clinical use of vancomycin","volume":"60","author":"\u00c1lvarez","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"issue":"4","key":"2025123118585395600_r48","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/FTD.0000000000001293","article-title":"Multiple model optimal sampling promotes accurate vancomycin area-under-the-curve estimation using a single sample in critically ill children","volume":"47","author":"Downes","year":"2025","journal-title":"Ther Drug Monit."},{"issue":"2","key":"2025123118585395600_r49","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/jpids\/pix109","article-title":"Individualized empiric vancomycin dosing in neonates using a model-based approach","volume":"8","author":"Frymoyer","year":"2019","journal-title":"J Pediatric Infect Dis Soc."},{"issue":"8","key":"2025123118585395600_r50","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.3390\/biomedicines12081843","article-title":"Upholding or breaking the law of superposition in pharmacokinetics","volume":"12","author":"Yousef","year":"2024","journal-title":"Biomedicines."},{"issue":"4","key":"2025123118585395600_r51","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1023\/A:1021016218536","article-title":"The formulation of the principle of superposition in the presence of non-compliance and its applications in multiple dose pharmacokinetics","volume":"26","author":"Wang","year":"1998","journal-title":"J Pharmacokinet Biopharm."},{"issue":"1","key":"2025123118585395600_r52","doi-asserted-by":"crossref","first-page":"e0146224","DOI":"10.1371\/journal.pone.0146224","article-title":"Association between the AUC0-24\/MIC ratio of vancomycin and its clinical effectiveness: a systematic review and meta-analysis","volume":"11","author":"Men","year":"2016","journal-title":"PLoS One."},{"issue":"11","key":"2025123118585395600_r53","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00228-017-2306-3","article-title":"Determining the optimal vancomycin daily dose for pediatrics: a meta-analysis","volume":"73","author":"da Silva Alves","year":"2017","journal-title":"Eur J Clin Pharmacol."},{"issue":"3","key":"2025123118585395600_r54","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.clinthera.2010.03.005","article-title":"Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections: a Monte Carlo simulation","volume":"32","author":"Frymoyer","year":"2010","journal-title":"Clin Ther."},{"issue":"7","key":"2025123118585395600_r55","first-page":"740","article-title":"Comparing vancomycin area under the curve with a pharmacist protocol that incorporates trough and maximum doses at a children\u2019s hospital","volume":"26","author":"Al-Mazraawy","year":"2021","journal-title":"J Pediatr Pharmacol Ther."},{"issue":"7","key":"2025123118585395600_r56","first-page":"746","article-title":"Optimization of vancomycin dosing to achieve target area under the curve in pediatrics","volume":"26","author":"Bosley","year":"2021","journal-title":"J Pediatr Pharmacol Ther."},{"issue":"10","key":"2025123118585395600_r57","doi-asserted-by":"crossref","first-page":"e0089721","DOI":"10.1128\/AAC.00897-21","article-title":"Population pharmacokinetics and dosing optimization of vancomycin in infants, children, and adolescents with augmented renal clearance","volume":"65","author":"He","year":"2021","journal-title":"Antimicrob Agents Chemother."},{"issue":"10","key":"2025123118585395600_r58","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/phar.2845","article-title":"Impact of model-informed precision dosing on achievement of vancomycin exposure targets in pediatric patients with cystic fibrosis","volume":"43","author":"Frymoyer","year":"2023","journal-title":"Pharmacotherapy."},{"issue":"1","key":"2025123118585395600_r59","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/ppul.26190","article-title":"Retrospective review of vancomycin monitoring via trough only versus two-point estimated area under the curve in pediatric and adult patients with cystic fibrosis","volume":"58","author":"Mitchell","year":"2023","journal-title":"Pediatr Pulmonol."},{"issue":"2","key":"2025123118585395600_r60","doi-asserted-by":"crossref","first-page":"e0046021","DOI":"10.1128\/Spectrum.00460-21","article-title":"Population pharmacokinetics and dosing optimization of vancomycin in pediatric liver transplant recipients","volume":"9","author":"Shoji","year":"2021","journal-title":"Microbiol Spectr."},{"issue":"6","key":"2025123118585395600_r61","doi-asserted-by":"crossref","first-page":"103688","DOI":"10.1016\/j.bjid.2023.103688","article-title":"Pharmacokinetics and therapeutic target attainment of vancomycin in pediatric post-liver transplant patients","volume":"27","author":"Morales Junior","year":"2023","journal-title":"Braz J Infect Dis."},{"issue":"11","key":"2025123118585395600_r62","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1093\/jac\/dkab302","article-title":"Population pharmacokinetics of vancomycin in paediatric patients with febrile neutropenia and augmented renal clearance: development of new dosing recommendations","volume":"76","author":"Shimamoto","year":"2021","journal-title":"J Antimicrob Chemother."},{"issue":"4","key":"2025123118585395600_r63","first-page":"312","article-title":"Vancomycin treatment failure in children with methicillin-resistant Staphylococcus aureus bacteremia","volume":"24","author":"Regen","year":"2019","journal-title":"J Pediatr Pharmacol Ther."},{"issue":"June","key":"2025123118585395600_r64","doi-asserted-by":"crossref","first-page":"867712","DOI":"10.3389\/fped.2022.867712","article-title":"Clinical application value of pharmacokinetic parameters of vancomycin in children treated in the pediatric intensive care unit","volume":"10","author":"Zhou","year":"2022","journal-title":"Front Pediatr."},{"issue":"4","key":"2025123118585395600_r65","doi-asserted-by":"crossref","first-page":"e0247714","DOI":"10.1371\/journal.pone.0247714","article-title":"Impact of initial vancomycin pharmacokinetic\/ pharmacodynamic parameters on the clinical and microbiological outcomes of methicillin-resistant Staphylococcus aureus bacteremia in children","volume":"16","author":"Yoo","year":"2021","journal-title":"PLoS One."},{"issue":"4","key":"2025123118585395600_r66","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jiac.2023.10.025","article-title":"A cohort study of the risk factors and the target AUC to avoid vancomycin-associated acute kidney injury in pediatric patients","volume":"30","author":"Kanazawa","year":"2024","journal-title":"J Infect Chemother."},{"issue":"6","key":"2025123118585395600_r67","doi-asserted-by":"crossref","first-page":"2022058813","DOI":"10.1542\/peds.2022-058813","article-title":"Late-onset sepsis among very preterm infants","volume":"150","author":"Flannery","year":"2022","journal-title":"Pediatrics."},{"issue":"7","key":"2025123118585395600_r68","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00228-018-2454-0","article-title":"Population pharmacokinetics of vancomycin and AUC-guided dosing in Chinese neonates and young infants","volume":"74","author":"Chen","year":"2018","journal-title":"Eur J Clin Pharmacol."},{"issue":"3","key":"2025123118585395600_r69","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jiac.2016.11.009","article-title":"Assessment of optimal initial dosing regimen with vancomycin pharmacokinetics model in very low birth weight neonates","volume":"23","author":"Kato","year":"2017","journal-title":"J Infect Chemother."},{"issue":"3","key":"2025123118585395600_r70","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/jac\/dkab469","article-title":"Identifying a therapeutic target for vancomycin against staphylococci in young infants","volume":"77","author":"Gwee","year":"2022","journal-title":"J Antimicrob Chemother."},{"issue":"2","key":"2025123118585395600_r71","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/ejhpharm-2020-002479","article-title":"Vancomycin in neonatal sepsis: predictive performance of a Chinese neonatal population pharmacokinetic model and clinical efficacy evaluation","volume":"29","author":"Weng","year":"2022","journal-title":"Eur J Hosp Pharm."},{"issue":"3","key":"2025123118585395600_r72","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.pedneo.2021.11.010","article-title":"Optimal exposure targets for vancomycin in the treatment of neonatal coagulase-negative Staphylococcus infection: A retrospective study based on electronic medical records","volume":"63","author":"Chen","year":"2022","journal-title":"Pediatr Neonatol."},{"issue":"4","key":"2025123118585395600_r73","doi-asserted-by":"crossref","first-page":"106958","DOI":"10.1016\/j.ijantimicag.2023.106958","article-title":"Association between vancomycin therapeutic drug monitoring and clinical outcomes in treating neonatal sepsis","volume":"62","author":"Chung","year":"2023","journal-title":"Int J Antimicrob Agents."},{"issue":"11","key":"2025123118585395600_r74","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/ajhp\/zxad048","article-title":"Considerations for implementation of vancomycin Bayesian software monitoring in a level IV NICU population within a multisite health system","volume":"80","author":"Oliver","year":"2023","journal-title":"Am J Health Syst Pharm."},{"issue":"9","key":"2025123118585395600_r75","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.3390\/antibiotics11091164","article-title":"Tissue penetration of antimicrobials in intensive care unit patients: a systematic review-part I","volume":"11","author":"Finazzi","year":"2022","journal-title":"Antibiotics (Basel)."},{"issue":"9","key":"2025123118585395600_r76","first-page":"1","article-title":"Tissue penetration of antimicrobials in intensive care unit patients: a systematic review-part II","volume":"11","author":"Viaggi","year":"2022","journal-title":"Antibiotics (Basel)."},{"issue":"38","key":"2025123118585395600_r77","doi-asserted-by":"crossref","first-page":"5769","DOI":"10.2174\/1381612823666170926121124","article-title":"Developmental pharmacokinetics in neonates: maturational changes and beyond","volume":"23","author":"Allegaert","year":"2017","journal-title":"Curr Pharm Des."},{"issue":"8","key":"2025123118585395600_r78","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s10096-018-3277-8","article-title":"Factors impacting unbound vancomycin concentrations in neonates and young infants","volume":"37","author":"Smits","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis."},{"issue":"11","key":"2025123118585395600_r79","doi-asserted-by":"crossref","first-page":"7073","DOI":"10.1128\/AAC.01185-15","article-title":"Factors impacting unbound vancomycin concentrations in different patient populations","volume":"59","author":"Oyaert","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"issue":"9","key":"2025123118585395600_r80","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1080\/17425255.2019.1655540","article-title":"Pharmacokinetic modelling and Bayesian estimation-assisted decision tools to optimize vancomycin dosage in neonates: only one piece of the puzzle","volume":"15","author":"Allegaert","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol."},{"issue":"12","key":"2025123118585395600_r81","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/ajhp\/zxz070","article-title":"Readiness to implement vancomycin monitoring based on area under the concentration-time curve: A cross-sectional survey of a national health consortium","volume":"76","author":"Kufel","year":"2019","journal-title":"Am J Health Syst Pharm."},{"issue":"6","key":"2025123118585395600_r82","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1177\/0897190019834369","article-title":"Vancomycin area under the curve dosing and monitoring at an academic medical center: transition strategies and lessons learned","volume":"33","author":"Gregory","year":"2020","journal-title":"J Pharm Pract."},{"issue":"4","key":"2025123118585395600_r83","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/phar.2234","article-title":"Conversion from vancomycin trough concentration-guided dosing to area under the curve-guided dosing using two sample measurements in adults: implementation at an academic medical center","volume":"39","author":"Meng","year":"2019","journal-title":"Pharmacotherapy."},{"issue":"1","key":"2025123118585395600_r84","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1177\/08971900211027271","article-title":"Doing more with less: pragmatic implementation of vancomycin area-under-the-curve (AUC) monitoring","volume":"36","author":"Huang","year":"2023","journal-title":"J Pharm Pract."},{"issue":"2","key":"2025123118585395600_r85","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4212\/cjhp.v75i2.3114","article-title":"Methods of therapeutic drug monitoring to guide vancomycin dosing regimens: trough concentration versus ratio of area under the curve to minimum inhibitory concentration","volume":"75","author":"Sault","year":"2022","journal-title":"Can J Hosp Pharm."},{"issue":"8","key":"2025123118585395600_r86","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1177\/10600280221141402","article-title":"Efficacy and safety of vancomycin Bayesian-estimated area under the curve versus trough-based dosing","volume":"57","author":"Cerenzio","year":"2023","journal-title":"Ann Pharmacother."},{"issue":"11","key":"2025123118585395600_r87","doi-asserted-by":"crossref","first-page":"ofae600","DOI":"10.1093\/ofid\/ofae600","article-title":"Implementation of a pharmacist-driven vancomycin area under the concentration-time curve monitoring program using Bayesian modeling in outpatient parenteral antimicrobial therapy","volume":"11","author":"Gillett","year":"2024","journal-title":"Open Forum Infect Dis."},{"issue":"9","key":"2025123118585395600_r88","doi-asserted-by":"crossref","first-page":"1346.e1","DOI":"10.1016\/j.cmi.2020.11.008","article-title":"Cost-benefit analysis comparing trough, two-level AUC and Bayesian AUC dosing for vancomycin","volume":"27","author":"Lee","year":"2021","journal-title":"Clin Microbiol Infect."},{"issue":"3","key":"2025123118585395600_r89","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/jac\/dkaf011","article-title":"Therapeutic drug monitoring versus Bayesian AUC-based dosing for vancomycin in routine practice: a cost-benefit analysis","volume":"80","author":"Claus","year":"2025","journal-title":"J Antimicrob Chemother."},{"issue":"5","key":"2025123118585395600_r90","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.japh.2020.02.025","article-title":"Cost comparison of AUC:MIC- versus trough-based vancomycin monitoring for MRSA bacteremia","volume":"60","author":"Beccari","year":"2020","journal-title":"J Am Pharm Assoc (Wash DC)."},{"issue":"3","key":"2025123118585395600_r91","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/jpids\/piz036","article-title":"Intravenous vancomycin therapeutic drug monitoring in children: Evaluation of a pharmacy-driven protocol and collaborative practice agreement","volume":"9","author":"Olson","year":"2020","journal-title":"J Pediatric Infect Dis Soc."},{"issue":"4","key":"2025123118585395600_r92","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1038\/psp.2013.14","article-title":"Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods","volume":"2","author":"Mould","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"key":"2025123118585395600_r93","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/B978-0-12-815849-4.00005-0","volume-title":"Therapeutic Drug Monitoring Data","author":"Dasgupta","year":"2020","edition":"4th ed"},{"issue":"8","key":"2025123118585395600_r94","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/17512433.2023.2224562","article-title":"Dried blood spot sampling for therapeutic drug monitoring: challenges and opportunities","volume":"16","author":"M\u00fcller","year":"2023","journal-title":"Expert Rev Clin Pharmacol."},{"issue":"9","key":"2025123118585395600_r95","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.3390\/antibiotics11091142","article-title":"Use of antibiotics in preterm newborns","volume":"11","author":"Simeoli","year":"2022","journal-title":"Antibiotics (Basel)."},{"key":"2025123118585395600_r96","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/B978-0-12-815849-4.00008-6","volume-title":"Therapeutic Drug Monitoring Data","author":"Dasgupta","year":"2020","edition":"4th ed"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2025-073013\/1901311\/pediatrics.2025073013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2025-073013\/1901311\/pediatrics.2025073013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T23:59:11Z","timestamp":1767225551000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/157\/1\/e2025073013\/205886\/Advances-in-Pediatric-Therapeutic-Drug-Monitoring"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":96,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,18]]},"published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2025-073013","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"article-number":"e2025073013"}}